YK012 is named as an intervention in 5 current clinical trials in our China register. 4 are recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Excyte Biopharma Ltd (4). The most-studied condition is System Lupus Erythematosus(SLE).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301 · ClinicalTrials.gov ↗ · B-cell Acute Lymphoblastic Leukemia
|
Phase 1/2 | Recruiting | Excyte Biopharma Ltd | China |
|
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
NCT07010835 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)
|
Phase 1/2 | Recruiting | Excyte Biopharma Ltd | China |
|
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT06565689 · ClinicalTrials.gov ↗ · Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
|
Phase 1 | Recruiting | Excyte Biopharma Ltd | China |
|
Study of YK012 in Primary Membranous Nephropathy
NCT06982729 · ClinicalTrials.gov ↗ · Primary Membranous Nephropathy
|
Phase 1 | Recruiting | Excyte Biopharma Ltd | China |
|
Study of YKST02 Alone or in Combination With YK012 in Patients With Active or Refractory Systemic Lupus Erythematosus
NCT07512947 · ClinicalTrials.gov ↗ · System Lupus Erythematosus(SLE)
|
Phase 1 | Not yet open | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Excyte Biopharma Ltd | 4 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 5 | 4 |
A trial with sites in more than one country appears in each of those registers.
5 current trials in our China register name YK012 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 5 trials are recruiting: 4 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Excyte Biopharma Ltd (4) and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how YK012 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how YK012 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists YK012 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.